NEW YORK, Sept. 12, 2017 -- Wolf Haldenstein Adler Freeman & Herz LLP announces that a federal securities class action lawsuit has been filed in the United States District Court for the Eastern District of New York on behalf of purchasers of the securities of Health Insurance Innovations, Inc. (NASDAQ:HIIQ) (the “Company”) from August 2, 2017 through September 11, 2017, both dates inclusive (the “Class Period”).
Investors who have incurred losses in Health Insurance Innovations, Inc. are urged to contact the firm immediately at [email protected] or (800) 575-0735 or (212) 545-4774. You may obtain additional information concerning the action on our website, www.whafh.com.
If you have purchased shares of Health Insurance Innovations, Inc. and would like to assist with the litigation process as a lead plaintiff, you may, no later than November 13, 2017, request that the Court appoint you lead plaintiff of the proposed class.
According to the filed complaint, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that:
- Health Insurance Innovations’ application for a third-party insurance administrators license with the Florida Office of Insurance Regulation was denied due in part to material errors and omissions;
- the Florida Office of Insurance Regulation’s rejection of Health Insurance Innovations’ application for a third-party insurance administrators license could result in its losing licenses in the other states; and
- as a result, Health Insurance Innovations’ public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.
On September 11, 2017, an article was published on SeekingAlpha.com alleging that in June 2017 one of Health Insurance Innovations' key license applications was rejected after regulators uncovered undisclosed legal actions against Company insiders; and that the Company privately warned a Florida regulator that a rejection of its license application could create a "domino effect" whereby licensing denials would spread to the other states.
On this news, Health Insurance Innovations' share price fell $6.55, or 21.91%, to close at $23.35 on September 11, 2017. The stock continued to plummet on September 12th, trading as low as $18.70 per share intraday, an additional decline of 20%.
Wolf Haldenstein has extensive experience in the prosecution of securities class actions and derivative litigation in state and federal trial and appellate courts across the country. The firm has attorneys in various practice areas; and offices in New York, Chicago and San Diego. The reputation and expertise of this firm in shareholder and other class litigation has been repeatedly recognized by the courts, which have appointed it to major positions in complex securities multi-district and consolidated litigation.
If you wish to discuss this action or have any questions regarding your rights and interests in this case, please immediately contact Wolf Haldenstein by telephone at (800) 575-0735, via e-mail at [email protected], or visit our website at www.whafh.com.
## Follow the firm and learn about newly filed cases on Twitter and Facebook. ##
Contact:
Wolf Haldenstein Adler Freeman & Herz LLP
Kevin Cooper, Esq.
Gregory Stone, Director of Case and Financial Analysis
Email: [email protected], [email protected] or [email protected]
Tel: (800) 575-0735 or (212) 545-4774
Attorney Advertising. Prior results do not guarantee or predict a similar outcome.


UAE's Largest Natural Gas Facility Suspended After Attack-Triggered Fire
Tesla Q1 2026 Deliveries Miss Estimates as AI Strategy Takes Center Stage
CTOC Adds 3,000 Doctors, 500 Hospitals Ahead of Liquidity Push
Fonterra Admits Anchor Butter "Grass-Fed" Label Misled Consumers After Greenpeace Lawsuit
Europe's Aviation Sector on Track to Meet 2025 Green Fuel Mandate
Trump Administration Plans 100% Tariffs on Pharmaceutical Imports
Nike Beats Q3 Estimates but China Weakness and Margin Pressure Weigh on Outlook
RBC Capital: European Medtech Firms Show Minimal Middle East and Energy Risk Exposure
MATCH Act Targets ASML and Chinese Chipmakers in New U.S. Export Crackdown
KPMG UK Cuts 440 Audit Jobs Amid Low Attrition and Cooling Professional Services Demand
Eli Lilly and Insilico Medicine Forge $2.75 Billion AI-Driven Drug Discovery Deal
Private Credit Under Pressure: Is a Slow-Motion Crisis Unfolding?
TSMC Japan's Second Fab to Produce 3nm Chips by 2028
Microsoft Eyes $7B Texas Energy Deal to Power AI Data Centers
Cathay Pacific Holds Firm on Flight Capacity Amid Middle East Conflict and Rising Fuel Costs
Jefferies Upgrades Sodexo to Buy With €55 Target After Historic CEO Appointment
Luxury Car Sales in the Middle East Take a Hit Amid Iran War 



